Search
Boji Pharmaceutical Secures Approval for Drug Clinical Trial
2 week ago /
Read about 0 minute
Author：小编
Boji Pharmaceutical has recently obtained authorization from the National Medical Products Administration to initiate clinical trials for the FCZR drug. Targeted at treating otomycosis, FCZR falls under the chemical drug classification of 2.2/2.4. The unique dosage form of FCZR is designed for ease of flow and administration, and it stands as an innovative offering with no direct market competitors, both domestically and internationally. This approval signifies a crucial milestone in Boji Pharmaceutical's new drug research and development endeavors, although it does not immediately have a significant impact on the company's operating performance.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
